News Archives - Page 2 of 3

July 19, 2024

Plasmids for Lentivirus and AAV Manufacturing

Lentiviruses and adeno-associated viruses (AAV) require specific plasmids for their production, which ensure efficient vector generation and safe delivery of the gene of interest (GOI).

https://anemocyte.com/wp-content/uploads/2024/07/AMC_News_pDNA_1200x900px_prev.png 1201 900 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2024/07/AMC_News_pDNA_1200x900px_prev.png July 19, 2024 July 19, 2024

June 17, 2024

mRNA Manufacturing Process

Many people first became familiar with the term “mRNA” when COVID-19 vaccines were rolled out. In the simplest terms, mRNA, which stands for messenger ribonucleic acid, is a genetic material that instructs the cells to make specific proteins.

https://anemocyte.com/wp-content/uploads/2024/06/AMC_News_mRNA-prev-1.jpg 1200 900 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2024/06/AMC_News_mRNA-prev-1.jpg June 17, 2024 July 17, 2024

October 4, 2023

Cell and Gene: meeting on the mesa

Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in Miami

https://anemocyte.com/wp-content/uploads/2023/10/AMC_2023-CellGene.jpg 1200 900 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2023/10/AMC_2023-CellGene.jpg October 4, 2023 May 27, 2024

February 18, 2020

La medicina del futuro è bio e “su misura”

https://anemocyte.com/wp-content/uploads/2020/02/AMC_news.jpg 1200 900 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2020/02/AMC_news.jpg February 18, 2020 May 15, 2024

February 18, 2020

Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in Miami

https://anemocyte.com/wp-content/uploads/2020/02/AMC_phacilitate_anteprima-3-scaled.jpg 2560 1958 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2020/02/AMC_phacilitate_anteprima-3-scaled.jpg February 18, 2020 May 15, 2024

February 2, 2020

How Anemocyte is Changing History as a Biotech Manufacturing Organization (BMO)

https://anemocyte.com/wp-content/uploads/2020/02/AMC_news.jpg 1200 900 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2020/02/AMC_news.jpg February 2, 2020 May 15, 2024

January 24, 2020

Anemocyte brings Italian excellence in the Cell and Gene Therapy sector to Phacilitate Leaders World 2020 in Miami

At the cutting edge of Cell and Gene therapy and a centre of excellence for the production of plasmids and non-viral solutions for genetic modifications, Anemocyte will be a key player at the leading sector event thanks to its expertise, dynamism and industrial cell and plasmid manufacturing facilities

https://anemocyte.com/wp-content/uploads/2020/01/AMC_brings_anteprima-scaled.jpg 2560 1315 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2020/01/AMC_brings_anteprima-scaled.jpg January 24, 2020 May 15, 2024

September 9, 2019

Italian Biotech Raises €13M to Test Stem Cell Therapy for Cancer

The Italian biotech Genenta Science has raised €13.2M in a private round to fund two ongoing phase I/II trials of its stem cell therapy Temferon for blood and brain cancer

https://anemocyte.com/wp-content/uploads/2019/09/Schermata-2019-11-06-alle-15.10.27.png 1610 792 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2019/09/Schermata-2019-11-06-alle-15.10.27.png September 9, 2019 May 15, 2024

July 16, 2019

Anemocyte to expand its plasmid manufacturing capabilities

A new state-of-the-art facility dedicated to plasmid manufacturing will be in operation by August 2019 in Gerenzano, Italy. The new site will couple with the existing GMP facility active in the Cell and Gene (C&G) therapy space. With 800m2 (8,000 square feet) of cleanrooms, the two facilities of Anemocyte, the first Biotech Manufacturing Organisation (BMO), will address manufacturing needs of Somatic Cells, Non-Viral Modified Cells, Vesicles and Plasmids for Viral Vectors

https://anemocyte.com/wp-content/uploads/2023/09/AMC_News-PlasmidManufacturing_.jpg 1200 450 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2023/09/AMC_News-PlasmidManufacturing_.jpg July 16, 2019 May 15, 2024

July 5, 2019

Drones Land in the Cell and Gene Therapy Space

Cell and gene therapies could be flying high soon, joining the medical supplies, whole blood products, and even organs being transported by drones. In collaboration with RPS Aerospace, the Italy-based biotech company Anemocyte developed a remotely piloted drone system to securely transport final cell and gene therapy products from manufacturing sites to clinical centers

https://anemocyte.com/wp-content/uploads/2019/07/AMC_drone_anteprima-scaled.jpg 2560 1556 Anemocyte Anemocyte https://anemocyte.com/wp-content/uploads/2019/07/AMC_drone_anteprima-scaled.jpg July 5, 2019 May 15, 2024